JORDAN GOODIN: Open Payments
NPI 1639949928 · MEXICO, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$903 in 51 payments from 16 companies in 2025. Trend: 2023 $215 · 2024 $467 · 2025 $903
Food & beverage: $903
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 10 | $185 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $117 |
| Otsuka America Pharmaceutical, Inc. | 5 | $106 |
| Vanda Pharmaceuticals Inc. | 5 | $99 |
| Lundbeck LLC | 4 | $75 |
| ABBVIE INC. | 4 | $66 |
| Alkermes, Inc. | 3 | $53 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Supernus Pharmaceuticals, Inc. | 2 | $34 |
| AstraZeneca Pharmaceuticals LP | 2 | $31 |
Products named: INGREZZA, REXULTI, CAPLYTA, FANAPT, VRAYLAR, ABILIFY MAINTENA, VIVITROL, Qelbree.
Industry payments across MO — which companies pay providers there.
